[Previous Months][Date Index][Thread Index][Join - Register][Login]
[Message Prev][Message Next][Thread Prev][Thread Next]
[IP] Re: Glargine
This article originally appeared in Diabetes Wellness Letter, November
1998, pages 1-3.
"------ another long-acting insulin analog from the third player in the
world insulin market is generating a lot of excitement.
Hoechst Marion Roussel is developing insulin glargine (HOE901), which,
Campbell says, will be next most important insulin development following
the introduction of lispro two years ago. "That is because it lasts for
24 hours," he says. "It doesn't have peaks and valleys, so it truly is a
basal depot insulin, and that should be very beneficial. The bad news
about it is that it is not mixable with other insulins, so people may have
to take an extra shot to use it."
The fact that insulin glargine can't be mixed with other insulins would be
bad news only in an ideal world, believes Eberhard Draeger, global project
leader and senior director of Hoechst Marion Roussel Inc. in Bridgewater,
New Jersey. It has the advantage, he says, of being given at once daily at
bedtime, providing a fixed regime that patients can easily follow.
Insulin glargine differs from human insulin in three amino acids, slowing
down its release and reducing its solubility in the blood. Phase III
clinical studies are currently ongoing, and Hoechst Marion Roussel expects
to make a U.S. submission next year. It should be available on the U.S.
market in 2000, Draeger says.
When insulin glargine and perhaps other long-acting insulin analogs become
available, people with diabetes will be able to combine a true basal
insulin with a rapid-acting insulin like lispro or aspart with their meals.
Draeger believes that this promises to be our best weapon yet for really
tight control, thereby reducing the onset and severity of eye, kidney, and
Insulin Pumpers website http://www.insulin-pumpers.org/
for mail subscription assistance, contact: HELP@insulin-pumpers.org